Earlier in this month of April, CROèe’s Oncology Team recently organized a felicitation seminar in Kyoto in honor of the Year 2018 Noble Laureate, Professor Honjo Tasuku, wherein the Noble Laureate received accolades for his outstanding work in the oncology field. Additionally, he was also thanked for saving and altering the lives of numerous cancer patients.

Professor Honjo Tasuku, of Kyoto University, is the Nobel Prize winner for year 2018 in the field of Medicines and Physiology for his creation and development of the ground-breaking therapeutic drug that has proven to harness and cure the formidable disease of cancer in several cases.
The felicitation seminar was held in Kyoto, earlier this month of April, wherein Professor Honjo delivered a speech before an overwhelming crowd of over two hundred audiences, which mainly consisted of cancer patients, their family members and researchers.
One of the main highlights of this event was the participation of Koichi Shimizu (41) of Sakura City, Chiba Prefecture, who has emerged successful from his treatment for Lung Cancer with Professor Honjo’s cancer drug Nivolumab, marketed as Opdivo. Mr. Shimizu took on this opportunity to look back at his treatment and thereby thanked Professor Honjo; “Had it not been for Professor Honjo’s research, I would not have been alive to see my child grow up. Not only has he saved my life but also brought about a positive change in my family’s life”, he reflected emotionally in his gratitude speech during the seminar.

During his interaction with CROèe personnel, Professor Honjo discussed the limitations of the cancer drugs, “one, it works for the limited fraction of the patient, and also, we have to improve the efficacy for two aspects,” he informed. He further described the two aspects as “predictive marker for responder versus non-responder, and improvement for the efficacy”. Professor Honjo is anticipating further development of the drug. He expects that the existing concerns related to the drug will soon be resolved owing to the fact that, even currently, several companies and scientists from the oncology field are relentlessly involved in addressing the issues and consequently will be able to further develop this already much celebrated cancer drug.

CROèe Inc, sees Professor Honjo’s aspirations for his revolutionary cancer drugs as a promising chance for the thousands of hopeless cancer victims out there, who may have fair chances of gaining back their health from the relevant clinical trials of such drugs. Certainly, even before the Noble Laureate’s drug has reached its optimum efficacy, it already has attained the power to change the lives of Cancer affected patients as well as their family members!

Please write us to know more about our holistic approach to reach the Cancer patients in Japan as well as in Asia. imran@croee.com